Last reviewed · How we verify
Recombinant ADAMTS13 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant ADAMTS13 (Recombinant ADAMTS13) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant ADAMTS13 TARGET | Recombinant ADAMTS13 | Takeda | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant ADAMTS13 CI watch — RSS
- Recombinant ADAMTS13 CI watch — Atom
- Recombinant ADAMTS13 CI watch — JSON
- Recombinant ADAMTS13 alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant ADAMTS13 — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-adamts13. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing